Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease
Overall, we have demonstrated that loss of mARC1 alters hepatocyte response to lipotoxic stress and protects mice from diet-induced MASH and liver fibrosis consistent with findings from human genetics.
Authors
- Heather Zhou
- Ester Carballo‐Jane
- Yongqi Zhou (ORCID: https://orcid.org/0000-0002-6237-5321)
- Tiffany Yang (ORCID: https://orcid.org/0000-0002-9687-6669)
- Darwin Lee
- Saswata Talukdar (ORCID: https://orcid.org/0000-0003-3042-0025)
- Brendan Gongol (ORCID: https://orcid.org/0000-0001-9627-613X)
- Wendy M. Blumenschein (ORCID: https://orcid.org/0009-0007-1175-9361)
- Asad Ali (ORCID: https://orcid.org/0000-0002-9327-1285)
- Desiree Abdurrachim
- Yang Liu (ORCID: https://orcid.org/0000-0003-1512-6362)
- Sentibel Pandovski
- Stacey Meyers
- Yilin Nie
- Thomas W. Rosahl
- Yingjiang Zhou
- Erin S. Coyne (ORCID: https://orcid.org/0000-0002-7746-9478)
- Christopher Hendra
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Quantitative BioSciences (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1097/hc9.0000000000000637
- Citations
- 8
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.83